Join us on 12 September 2024, for an insightful session on adapting and applying risk management plans (RMPs) effectively. Learn how to leverage digital tools and platforms to enhance RMP monitoring and implementation. Register for the webinar. https://ow.ly/4E7X50SE81V #Pharma #PatientSafety #RegulatoryAffairs #Webinar
About us
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
- Website
-
http://www.iconplc.com
External link for ICON plc
- Industry
- Biotechnology Research
- Company size
- 10,001+ employees
- Headquarters
- Dublin
- Type
- Public Company
- Specialties
- Medical Device, Therapeutics, Government and Public Health Solutions, Clinical Research Services, Commercialisation and Outcomes, Oncology, Value Based Healthcare, Clinical Trials, Patient Recruitment, Innovation, Regulatory Affairs, Strategic Consulting, Medical Affairs, and Global Patient Insights & Engagement
Locations
Employees at ICON plc
Updates
-
Bioanalysis of immunogenicity is critical for the development of therapeutic proteins, as immunogenicity can affect both the safety and efficacy of biologic drugs. High-quality approaches for tiered detection, characterization, or quasi-quantification of anti-drug antibodies (ADAs) require up-to-date knowledge of analytical methodologies, regulatory guidelines and industry best practices. To ensure high-quality approaches for immunogenicity testing, it is necessary to grasp a wide understanding of the needs and expectations of companies that are developing drugs that may initiate immunogenicity. Flexibility in approaches is needed to serve the different needs of each program. In this Spotlight hosted by Bioanalysis Zone we explore the elements involved in the different approaches for immunogenicity assessment, including preclinical ADA assessments, singlicate ADA analysis, or complex assay strategies to determine ADAs for different compounds/antibody modalities. https://ow.ly/7tMR50SCg05
-
-
As we move swiftly through July, we wanted to reflect on an extraordinary June PRIDE month at ICON. This year's events featured a PRIDE history and dance music festival, engaging guest speakers, and Bracelet and Flag sales for PRIDE-related charities. Numerous office brunches and lunches united our employees, allies, and community members. The spirit of inclusivity resonated globally within ICON, fostering empathy and continued support. Our commitment to a diverse and inclusive environment remains steadfast, and we are proud of our collective strides. Thank you to everyone who participated and made this PRIDE month memorable. Follow the link to read more about Diversity, Inclusion and Belonging at ICON plc. https://ow.ly/O0Yr50SF3RN
-
-
-
-
-
+1
-
-
Early phase clinical research is key to refining the safety profile of new drugs and proof of concept, expanding on the data gathered in preclinical studies. Ensuring participant safety requires strategic planning at multiple levels, from protocol and dose escalation to personnel training. ICON is continuously implementing proactive participant safety measures to effectively mitigate risks in early phase studies, with regular safety drills being performed by both clinic and hospital staff to ensure highly coordinated response and execution. We have also introduced the Modified Early Warning Score (MEWS) - this is designed to identify disturbances in vital parameters and prevent further serious risk to the trial participant. Read our blog to find out more. https://ow.ly/eG6x50StFvZ #earlyphase
-
-
PSI’s annual conference attracts pharmaceutical statisticians from around the world, including from ICON. This year our experts presented their insights on digital health technology and learned about the emerging trends in biostatistics. Read their takeaways in our blog. https://ow.ly/BKBk50SCn7o #psi #digitalhealthtechnologies #DHT
-
-
Last month, on June 19th, many of our colleagues in the US celebrated Juneteenth, a national holiday that honors the end of slavery in the United States. Our US-based offices marked the occasion with various events, fostering education, unity, and reflection. From ice cream socials and history lessons to lunches and more, our teams came together to learn and celebrate. Below are some photographs from our Wilmington & Raleigh offices. Additionally, here is a video about our EmbRACE community group at ICON: https://ow.ly/8vFZ50SF666.
-
-
-
-
-
+1
-
-
ICON expert, Jack Martin shares insights with BioSpectrum Asia on emerging trends in obesity treatment and the future implications for pharma. “Historically, methods of treating obesity have been limited. Lifestyle modification rarely takes into account significant risk factors, including genetics, environment and other elements outside a patient’s control. Recent developments, including the approval of GLP-1 receptor agonists, such as semaglutide, to treat obesity have sparked excitement in the field.” Learn more. https://ow.ly/OyK750Sztbn
-
-
In the CRO Leadership Awards 2024, ICON rated as having exceeded customer expectations in the Expertise category. ICON also received Individual Attribute Awards for operational excellence and for its therapeutic expertise. The awards are based on impartial market research of sponsor companies that utilise our services. Learn more here: https://ow.ly/x3aV50Sq3HZ #CROLeadershipAward #ExcellenceInClinicalResearch
-
-
ICON plc reposted this
"A development race is currently underway in the field of combination vaccines, with a number of influential pharmaceutical and biotech companies pursuing combination vaccines targeting influenza and COVID-19" In our latest blog post, Richard Pitman, PhD & Rosanna Barnard, PhD from ICON plc share what needs to happen before combination vaccines can be adopted: https://lnkd.in/gzVQMYhn
-
-
Mackenzie Bentley - Manager, Bioanalytical Services at ICON will be speaking at the #AAPS Summer Scientific Forum 2024. Join her rapid fire session on July 24 at 3:30 PM to understand the importance of the different approaches to matrix effect testing for protein biomarkers vs small molecule biomarkers. https://ow.ly/zz6y50SwVX0
-